Trial on The Efficacy of Hypertonic Saline on Non-CF CSLD.
Primary Purpose
Bronchiectasis
Status
Recruiting
Phase
Phase 4
Locations
Malaysia
Study Type
Interventional
Intervention
Nebulized 5% Hypertonic saline
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Bronchiectasis focused on measuring CSLD, Child, Nebuliser, Hypertonic Saline, Outcome, Chronic cough
Eligibility Criteria
Inclusion Criteria:
- Patients < 18 years old
- Followed up in the paediatric respiratory clinic of UMMC with a diagnosis of CSLD
Exclusion Criteria:
- Incomplete data or refusal to participate
- Unwell and/or unable to stop HS and/or antibiotics of any preparation other than azithromycin ( EOD
- On supplementary oxygen/home ventilation
- Poorly controlled asthma (as in the GINA guidelines) or bronchoconstriction that precedes the use of hypertonic saline.
- Oral antibiotics for less than 4 weeks before randomization for medication.
- Fall in PEFR > 20% post 5% HS challenge test or a positive HS challenge test in young children, as mentioned below.
Sites / Locations
- University Malaya Medical CentreRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
5% Hypertonic saline
Placebo
Arm Description
5% hypertonic saline nebuliser 4 mls twice in a day for 3 months
0.9% saline nebuliser 4 mls twice in a day for 3 months
Outcomes
Primary Outcome Measures
Change in the Short Parent-proxy cough quality of life (PC-QOL) score
Short PCQOL: This is a validated cough quality-of-life(QoL) questionnaire for parents of children with chronic cough, with a translated Malay version. Minimal Important Difference(MID) of 0.9 has been found in the validation study.
The answers are on a Likert scale from 1 (every time) to 7( none). A lower score denotes a lower quality of life.
The patients will answer either the English or the translated Malay version
Change in the Chronic Cough-specific QoL(CC-QOL) score
Chronic cough-specific QOL: This is a validated cough QoL questionnaire to be answered by children 7 years till 18 years old with a MID of about 1.1. The answers are in a Likert scale from 1 ( every time) to 7( none). A lower score denotes a lower quality of life.
The patients will answer either the English or the translated Malay version
Secondary Outcome Measures
Airway microbiome
DNA will be extracted from swabs using the Qiagen DNA Isolation Kit in accordance with the manufacturer's instructions. Bacterial profiling utilised the 16S rRNA gene targeting variable regions V3 - V4 will be carried out using Nextseq 2500 platform. Resulting raw fastq data will be processed using Dada2 R package and exported into phyloseq Rprogram for downstream analysis. The Alpha diversity will be measured using the Shannon and Simpson diversity indices while the beta diversity will be accessed using principle coordinate analysis and Permutational multivariate analysis of variance(PERMANOVA). Differentially abundant taxa will be identified by comparing the fold-change different using DESeq2.
Number of Exacerbations
Defined as having one major and 2 minor OR 2 major criteria irrespective of whether antibiotics are prescribed.
Criteria for exacerbation:
Major: (1) Wet cough over 72 hours, (2) Severe cough over 72 hours Minor: (1) Change in Sputum colour, (2) Chest pain, (3) SOB, (4) Haemoptysis, (5) + ve Chest signs
At -1 month, we will look at the no of exacerbations in the past 1 year. Before the use of the study drug and after 3 months of use of the study drug, we will look at the no of exacerbations in the preceding 1 month and 3 months, respectively.
Number of Unscheduled Health Care Visits
any unscheduled doctor visits for cough, shortness of breath or any other respiratory associated symptom.
This will be for the last 3 months before day 1 of randomization and after 3 months of use of study drug
No of episodes of rescue antibiotics
Prescription of antibiotics (including nebulized antibiotics) at least for 3 days for respiratory associated symptoms.
This will be in the past 3 months, before randomization and during the next 3 months, while on the study drug.
FEV1
FEV1 will be performed in sitting position(both pre and post 4 puffs of MDI Salbutamol) using the portable spirometry, performed in clinic. The best spirometric measure of at least 3 reproducible attempts will be recorded for analysis. Reference values from Morris/Polgar will be used with ethnic corrections. FEV1 value will be converted into z-score by using GrowingLungs software.
FVC
FVC will be performed in sitting position(both pre and post 4 puffs of MDI Salbutamol) using the portable spirometry, performed in clinic. The best spirometric measure of at least 3 reproducible attempts will be recorded for analysis. Reference values from Morris/Polgar will be used with ethnic corrections. FVC value will be converted into z-score by using GrowingLungs software.
FEF 25-75%
FEF 25-75% will be performed in sitting position(both pre and post 4 puffs of MDI Salbutamol) using the portable spirometry, performed in clinic. The best spirometric measure of at least 3 reproducible attempts will be recorded for analysis. Reference values from Morris/Polgar will be used with ethnic corrections. FEF25-75% value will be converted into z-score by using GrowingLungs software.
PEFR ( pre and post), if possible
The best PEFR measure out of 3 reproducible attempts ( both pre and post 4 puffs of MDI Salbutamol), performed when relatively well and stable, will be recorded for analysis.
Cough diary
The cough score will be assessed using the Malay version, used in the HOspitalised Pneumonia Extended study, whereby the cough score will be tabulated daily.
The cough diary has recordings for both day time cough: score 0 ( no cough) till score 5 ( Cannot perform most usual day-time activity due to severe coughing).
The night cough is scored score 0 ( no cough) till score 5 ( distressing cough.).
A higher score indicates more severe cough.
Number of Adverse events
cough, haemoptysis, sore throat, throat burning, chest tightness, hoarseness of voice.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04765033
Brief Title
Trial on The Efficacy of Hypertonic Saline on Non-CF CSLD.
Official Title
Efficacy of Nebulised 5% Hypertonic Saline in Children With Chronic Suppurative Lung Disease
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
February 4, 2021 (Actual)
Primary Completion Date
August 28, 2022 (Anticipated)
Study Completion Date
August 28, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Malaya
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
To determine the efficacy of nebulized 5% hypertonic saline on cough severity and quality of life, in children with non-CF CSLD.
Secondary Aims:
To determine the:
Efficacy of nebulized 5% hypertonic saline on airway microbiome, pulmonary exacerbation rate, healthcare utilization, and rescue antibiotics.
Efficacy of nebulized 5% hypertonic saline on lung function
Adverse effects of nebulized 5% hypertonic saline in children
Detailed Description
Primary Aim:
To determine the efficacy of nebulized 5% hypertonic saline on cough severity and quality of life, in children with non-CF CSLD.
Here the investigators will be using validated pediatric cough questionnaires to asses this. Patients will answer these questionnaires at first recruitment ( -1 mth), at randomization (0 month) and after 3 mths of use of the nebulized study drug (+ 3 mths)
Secondary Aims:
To determine the:
Efficacy of nebulized 5% hypertonic saline on the airway microbiome, pulmonary exacerbation rate, healthcare utilization, and rescue antibiotics.
Here the investigators will be taking history on the exacerbations, use of antibiotics and healthcare utilization before and after use of the hypertonic saline. Furthermore, Nasopharyngeal swabs will be done to review possible changes in microbiota, again before and after use of the 5% HS.
Efficacy of nebulized 5% hypertonic saline on lung function. Here is investigators will be doing portable spirometry ( pre and post bronchodilator).
Patients will perform at randomization (0 month) and after 3 mths of use of the nebulized study drug (+ 3 mths)
Adverse effects of nebulized 5% hypertonic saline in children HS has been associated with side-effects. The investigators will monitor this. We will asses presence of these symptoms at randomization (0 month) and after 3 mths of use of the nebulized study drug (+ 3 mths) to ensure these are from the nebulizer.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bronchiectasis
Keywords
CSLD, Child, Nebuliser, Hypertonic Saline, Outcome, Chronic cough
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Factorial Assignment
Model Description
Double-blind Placebo-controlled trial
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Double-blind
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
5% Hypertonic saline
Arm Type
Active Comparator
Arm Description
5% hypertonic saline nebuliser 4 mls twice in a day for 3 months
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
0.9% saline nebuliser 4 mls twice in a day for 3 months
Intervention Type
Drug
Intervention Name(s)
Nebulized 5% Hypertonic saline
Intervention Description
nebulized
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Nebulized 0.9% saline
Intervention Description
Nebulised
Primary Outcome Measure Information:
Title
Change in the Short Parent-proxy cough quality of life (PC-QOL) score
Description
Short PCQOL: This is a validated cough quality-of-life(QoL) questionnaire for parents of children with chronic cough, with a translated Malay version. Minimal Important Difference(MID) of 0.9 has been found in the validation study.
The answers are on a Likert scale from 1 (every time) to 7( none). A lower score denotes a lower quality of life.
The patients will answer either the English or the translated Malay version
Time Frame
at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug
Title
Change in the Chronic Cough-specific QoL(CC-QOL) score
Description
Chronic cough-specific QOL: This is a validated cough QoL questionnaire to be answered by children 7 years till 18 years old with a MID of about 1.1. The answers are in a Likert scale from 1 ( every time) to 7( none). A lower score denotes a lower quality of life.
The patients will answer either the English or the translated Malay version
Time Frame
at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug
Secondary Outcome Measure Information:
Title
Airway microbiome
Description
DNA will be extracted from swabs using the Qiagen DNA Isolation Kit in accordance with the manufacturer's instructions. Bacterial profiling utilised the 16S rRNA gene targeting variable regions V3 - V4 will be carried out using Nextseq 2500 platform. Resulting raw fastq data will be processed using Dada2 R package and exported into phyloseq Rprogram for downstream analysis. The Alpha diversity will be measured using the Shannon and Simpson diversity indices while the beta diversity will be accessed using principle coordinate analysis and Permutational multivariate analysis of variance(PERMANOVA). Differentially abundant taxa will be identified by comparing the fold-change different using DESeq2.
Time Frame
At day 1 of randomization, at 3 months of use of study drug
Title
Number of Exacerbations
Description
Defined as having one major and 2 minor OR 2 major criteria irrespective of whether antibiotics are prescribed.
Criteria for exacerbation:
Major: (1) Wet cough over 72 hours, (2) Severe cough over 72 hours Minor: (1) Change in Sputum colour, (2) Chest pain, (3) SOB, (4) Haemoptysis, (5) + ve Chest signs
At -1 month, we will look at the no of exacerbations in the past 1 year. Before the use of the study drug and after 3 months of use of the study drug, we will look at the no of exacerbations in the preceding 1 month and 3 months, respectively.
Time Frame
at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug
Title
Number of Unscheduled Health Care Visits
Description
any unscheduled doctor visits for cough, shortness of breath or any other respiratory associated symptom.
This will be for the last 3 months before day 1 of randomization and after 3 months of use of study drug
Time Frame
at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug
Title
No of episodes of rescue antibiotics
Description
Prescription of antibiotics (including nebulized antibiotics) at least for 3 days for respiratory associated symptoms.
This will be in the past 3 months, before randomization and during the next 3 months, while on the study drug.
Time Frame
at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug
Title
FEV1
Description
FEV1 will be performed in sitting position(both pre and post 4 puffs of MDI Salbutamol) using the portable spirometry, performed in clinic. The best spirometric measure of at least 3 reproducible attempts will be recorded for analysis. Reference values from Morris/Polgar will be used with ethnic corrections. FEV1 value will be converted into z-score by using GrowingLungs software.
Time Frame
At day 1 of randomization, at 3 months of use of study drug
Title
FVC
Description
FVC will be performed in sitting position(both pre and post 4 puffs of MDI Salbutamol) using the portable spirometry, performed in clinic. The best spirometric measure of at least 3 reproducible attempts will be recorded for analysis. Reference values from Morris/Polgar will be used with ethnic corrections. FVC value will be converted into z-score by using GrowingLungs software.
Time Frame
At day 1 of randomization, at 3 months of use of study drug
Title
FEF 25-75%
Description
FEF 25-75% will be performed in sitting position(both pre and post 4 puffs of MDI Salbutamol) using the portable spirometry, performed in clinic. The best spirometric measure of at least 3 reproducible attempts will be recorded for analysis. Reference values from Morris/Polgar will be used with ethnic corrections. FEF25-75% value will be converted into z-score by using GrowingLungs software.
Time Frame
At day 1 of randomization, at 3 months of use of study drug
Title
PEFR ( pre and post), if possible
Description
The best PEFR measure out of 3 reproducible attempts ( both pre and post 4 puffs of MDI Salbutamol), performed when relatively well and stable, will be recorded for analysis.
Time Frame
at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug
Title
Cough diary
Description
The cough score will be assessed using the Malay version, used in the HOspitalised Pneumonia Extended study, whereby the cough score will be tabulated daily.
The cough diary has recordings for both day time cough: score 0 ( no cough) till score 5 ( Cannot perform most usual day-time activity due to severe coughing).
The night cough is scored score 0 ( no cough) till score 5 ( distressing cough.).
A higher score indicates more severe cough.
Time Frame
at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug
Title
Number of Adverse events
Description
cough, haemoptysis, sore throat, throat burning, chest tightness, hoarseness of voice.
Time Frame
At day 1 of randomization, at 3 months of use of study drug
10. Eligibility
Sex
All
Minimum Age & Unit of Time
3 Months
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients < 18 years old
Followed up in the paediatric respiratory clinic of UMMC with a diagnosis of CSLD
Exclusion Criteria:
Incomplete data or refusal to participate
Unwell and/or unable to stop HS and/or antibiotics of any preparation other than azithromycin ( EOD
On supplementary oxygen/home ventilation
Poorly controlled asthma (as in the GINA guidelines) or bronchoconstriction that precedes the use of hypertonic saline.
Oral antibiotics for less than 4 weeks before randomization for medication.
Fall in PEFR > 20% post 5% HS challenge test or a positive HS challenge test in young children, as mentioned below.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Anna M Nathan
Phone
603-79493643/ 0122123503
Email
psr9900@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anna M Nathan
Organizational Affiliation
UMMC
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Malaya Medical Centre
City
Kuala Lumpur
State/Province
Lembah Pantai
ZIP/Postal Code
59100
Country
Malaysia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anna M Nathan
Phone
60122123503
Email
psr9900@hotmail.com
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
Not to share
Citations:
PubMed Identifier
28265556
Citation
McCallum GB, Binks MJ. The Epidemiology of Chronic Suppurative Lung Disease and Bronchiectasis in Children and Adolescents. Front Pediatr. 2017 Feb 20;5:27. doi: 10.3389/fped.2017.00027. eCollection 2017.
Results Reference
result
PubMed Identifier
31409413
Citation
Lovie-Toon YG, Grimwood K, Byrnes CA, Goyal V, Busch G, Masters IB, Marchant JM, Buntain H, O'Grady KF, Chang AB. Health-resource use and quality of life in children with bronchiectasis: a multi-center pilot cohort study. BMC Health Serv Res. 2019 Aug 13;19(1):561. doi: 10.1186/s12913-019-4414-5.
Results Reference
result
PubMed Identifier
30215382
Citation
Chang AB, Bush A, Grimwood K. Bronchiectasis in children: diagnosis and treatment. Lancet. 2018 Sep 8;392(10150):866-879. doi: 10.1016/S0140-6736(18)31554-X. Erratum In: Lancet. 2018 Oct 6;392(10154):1196.
Results Reference
result
PubMed Identifier
24482322
Citation
Nathan AM, Muthusamy A, Thavagnanam S, Hashim A, de Bruyne J. Chronic suppurative lung disease in a developing country: impact on child and parent. Pediatr Pulmonol. 2014 May;49(5):435-40. doi: 10.1002/ppul.23001. Epub 2014 Jan 31.
Results Reference
result
PubMed Identifier
25638182
Citation
Kumar A, Lodha R, Kumar P, Kabra SK. Non-cystic fibrosis bronchiectasis in children: clinical profile, etiology and outcome. Indian Pediatr. 2015 Jan;52(1):35-7. doi: 10.1007/s13312-015-0563-8.
Results Reference
result
PubMed Identifier
21885727
Citation
Kapur N, Masters IB, Newcombe P, Chang AB. The burden of disease in pediatric non-cystic fibrosis bronchiectasis. Chest. 2012 Apr;141(4):1018-1024. doi: 10.1378/chest.11-0679. Epub 2011 Sep 1.
Results Reference
result
PubMed Identifier
12927665
Citation
Gaillard EA, Carty H, Heaf D, Smyth RL. Reversible bronchial dilatation in children: comparison of serial high-resolution computer tomography scans of the lungs. Eur J Radiol. 2003 Sep;47(3):215-20. doi: 10.1016/s0720-048x(02)00122-5.
Results Reference
result
PubMed Identifier
3533593
Citation
Cole PJ. Inflammation: a two-edged sword--the model of bronchiectasis. Eur J Respir Dis Suppl. 1986;147:6-15.
Results Reference
result
PubMed Identifier
29225146
Citation
Hahn A, Warnken S, Perez-Losada M, Freishtat RJ, Crandall KA. Microbial diversity within the airway microbiome in chronic pediatric lung diseases. Infect Genet Evol. 2018 Sep;63:316-325. doi: 10.1016/j.meegid.2017.12.006. Epub 2017 Dec 7.
Results Reference
result
PubMed Identifier
23646159
Citation
Zemanick ET, Harris JK, Wagner BD, Robertson CE, Sagel SD, Stevens MJ, Accurso FJ, Laguna TA. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations. PLoS One. 2013 Apr 30;8(4):e62917. doi: 10.1371/journal.pone.0062917. Print 2013.
Results Reference
result
PubMed Identifier
20585638
Citation
Cox MJ, Allgaier M, Taylor B, Baek MS, Huang YJ, Daly RA, Karaoz U, Andersen GL, Brown R, Fujimura KE, Wu B, Tran D, Koff J, Kleinhenz ME, Nielson D, Brodie EL, Lynch SV. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS One. 2010 Jun 23;5(6):e11044. doi: 10.1371/journal.pone.0011044.
Results Reference
result
PubMed Identifier
31475469
Citation
Prentice BJ, Wales S, Doumit M, Owens L, Widger J. Children with bronchiectasis have poorer lung function than those with cystic fibrosis and do not receive the same standard of care. Pediatr Pulmonol. 2019 Dec;54(12):1921-1926. doi: 10.1002/ppul.24491. Epub 2019 Sep 1.
Results Reference
result
PubMed Identifier
21458735
Citation
Chang AB. Bronchiectasis: so much yet to learn and to do. Paediatr Respir Rev. 2011 Jun;12(2):89-90. doi: 10.1016/j.prrv.2011.01.001. Epub 2011 Feb 2. No abstract available.
Results Reference
result
PubMed Identifier
11511368
Citation
Tarran R, Grubb BR, Parsons D, Picher M, Hirsh AJ, Davis CW, Boucher RC. The CF salt controversy: in vivo observations and therapeutic approaches. Mol Cell. 2001 Jul;8(1):149-58. doi: 10.1016/s1097-2765(01)00286-6.
Results Reference
result
PubMed Identifier
1285737
Citation
Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med. 1992 Apr 30;326(18):1187-91. doi: 10.1056/NEJM199204303261804.
Results Reference
result
PubMed Identifier
21330456
Citation
Reeves EP, Williamson M, O'Neill SJ, Greally P, McElvaney NG. Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med. 2011 Jun 1;183(11):1517-23. doi: 10.1164/rccm.201101-0072OC. Epub 2011 Feb 17.
Results Reference
result
PubMed Identifier
17053496
Citation
Elkins MR, Bye PT. Inhaled hypertonic saline as a therapy for cystic fibrosis. Curr Opin Pulm Med. 2006 Nov;12(6):445-52. doi: 10.1097/01.mcp.0000245714.89632.b2.
Results Reference
result
PubMed Identifier
18828160
Citation
Dellon EP, Donaldson SH, Johnson R, Davis SD. Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis. Pediatr Pulmonol. 2008 Nov;43(11):1100-1106. doi: 10.1002/ppul.20909.
Results Reference
result
PubMed Identifier
15672845
Citation
Kellett F, Redfern J, Niven RM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir Med. 2005 Jan;99(1):27-31. doi: 10.1016/j.rmed.2004.05.006.
Results Reference
result
PubMed Identifier
22018993
Citation
Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med. 2011 Dec;105(12):1831-5. doi: 10.1016/j.rmed.2011.07.019. Epub 2011 Oct 22.
Results Reference
result
PubMed Identifier
22349069
Citation
Nicolson CH, Stirling RG, Borg BM, Button BM, Wilson JW, Holland AE. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med. 2012 May;106(5):661-7. doi: 10.1016/j.rmed.2011.12.021. Epub 2012 Feb 19.
Results Reference
result
PubMed Identifier
28232410
Citation
Paff T, Daniels JM, Weersink EJ, Lutter R, Vonk Noordegraaf A, Haarman EG. A randomised controlled trial on the effect of inhaled hypertonic saline on quality of life in primary ciliary dyskinesia. Eur Respir J. 2017 Feb 23;49(2):1601770. doi: 10.1183/13993003.01770-2016. Print 2017 Feb.
Results Reference
result
PubMed Identifier
25307313
Citation
Sidhu MK, Mandal P, Hill AT. Developing drug therapies in bronchiectasis. Expert Opin Investig Drugs. 2015 Feb;24(2):169-81. doi: 10.1517/13543784.2015.971153. Epub 2014 Oct 11.
Results Reference
result
PubMed Identifier
24521788
Citation
Goyal V, Grimwood K, Marchant J, Masters IB, Chang AB. Does failed chronic wet cough response to antibiotics predict bronchiectasis? Arch Dis Child. 2014 Jun;99(6):522-5. doi: 10.1136/archdischild-2013-304793. Epub 2014 Feb 12.
Results Reference
result
PubMed Identifier
12403874
Citation
Chang AB, Boyce NC, Masters IB, Torzillo PJ, Masel JP. Bronchoscopic findings in children with non-cystic fibrosis chronic suppurative lung disease. Thorax. 2002 Nov;57(11):935-8. doi: 10.1136/thorax.57.11.935.
Results Reference
result
PubMed Identifier
20864608
Citation
Kapur N, Masel JP, Watson D, Masters IB, Chang AB. Bronchoarterial ratio on high-resolution CT scan of the chest in children without pulmonary pathology: need to redefine bronchial dilatation. Chest. 2011 Jun;139(6):1445-1450. doi: 10.1378/chest.10-1763. Epub 2010 Sep 23.
Results Reference
result
PubMed Identifier
26842959
Citation
Newcombe PA, Sheffield JK, Petsky HL, Marchant JM, Willis C, Chang AB. A child chronic cough-specific quality of life measure: development and validation. Thorax. 2016 Aug;71(8):695-700. doi: 10.1136/thoraxjnl-2015-207473. Epub 2016 Feb 3.
Results Reference
result
PubMed Identifier
27214047
Citation
Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods. 2016 Jul;13(7):581-3. doi: 10.1038/nmeth.3869. Epub 2016 May 23.
Results Reference
result
PubMed Identifier
23630581
Citation
McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One. 2013 Apr 22;8(4):e61217. doi: 10.1371/journal.pone.0061217. Print 2013.
Results Reference
result
PubMed Identifier
25516281
Citation
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi: 10.1186/s13059-014-0550-8.
Results Reference
result
PubMed Identifier
31023759
Citation
Chang AB, Fong SM, Yeo TW, Ware RS, McCallum GB, Nathan AM, Ooi MH, de Bruyne J, Byrnes CA, Lee B, Nachiappan N, Saari N, Torzillo P, Smith-Vaughan H, Morris PS, Upham JW, Grimwood K. HOspitalised Pneumonia Extended (HOPE) Study to reduce the long-term effects of childhood pneumonia: protocol for a multicentre, double-blind, parallel, superiority randomised controlled trial. BMJ Open. 2019 Apr 24;9(4):e026411. doi: 10.1136/bmjopen-2018-026411.
Results Reference
result
PubMed Identifier
21830316
Citation
Kapur N, Masters IB, Morris PS, Galligan J, Ware R, Chang AB. Defining pulmonary exacerbation in children with non-cystic fibrosis bronchiectasis. Pediatr Pulmonol. 2012 Jan;47(1):68-75. doi: 10.1002/ppul.21518. Epub 2011 Aug 9.
Results Reference
result
PubMed Identifier
18006882
Citation
Stanojevic S, Wade A, Stocks J, Hankinson J, Coates AL, Pan H, Rosenthal M, Corey M, Lebecque P, Cole TJ. Reference ranges for spirometry across all ages: a new approach. Am J Respir Crit Care Med. 2008 Feb 1;177(3):253-60. doi: 10.1164/rccm.200708-1248OC. Epub 2007 Nov 15.
Results Reference
result
PubMed Identifier
31055386
Citation
Walker PP, Key AL. How to perform peak flow and spirometry tests. BMJ. 2016 May 11;353:h6159. doi: 10.1136/sbmj.h6159. No abstract available.
Results Reference
result
PubMed Identifier
23146374
Citation
Newcombe PA, Sheffield JK, Chang AB. Parent cough-specific quality of life: development and validation of a short form. J Allergy Clin Immunol. 2013 Apr;131(4):1069-74. doi: 10.1016/j.jaci.2012.10.004. Epub 2012 Nov 10.
Results Reference
result
Learn more about this trial
Trial on The Efficacy of Hypertonic Saline on Non-CF CSLD.
We'll reach out to this number within 24 hrs